Earnings ·
Reports Q3 revenue of $22.2M, up 8% year over year
HBIOHarvard Bioscience Inc
Harvard Bioscience reported third-quarter 2026 revenues of $22.2 million, an 8% increase from the prior-year period's $20.6 million. The company posted a net loss of $(2.6) million compared to a $(1.2) million loss in the same quarter last year. Adjusted EBITDA was $1.8 million, down slightly from $2.0 million in the prior-year quarter. For the nine-month period, revenues reached $65.7 million against $62.8 million previously, with a net loss of $(9.0) million compared to $(53.9) million last year, largely due to a significant goodwill impairment recorded in early 2025. The company reaffirmed its full-year revenue growth guidance of 3%-5% and updated its adjusted EBITDA target range. Harvard Bioscience develops, manufactures, and sells technologies for life science applications including research, drug discovery, and preclinical testing.